Adherium (ASX:ADR)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Adherium.
RELATED STOCKHEAD STORIES
Dr Boreham’s Crucible: Sizing up the opportunity for ASX biotech Adherium
Health Check: Poly oh no! Polynovo shares resume slide as CEO goes
Health Check: Which biotech boards are at risk of a ‘second strike’?
Air supply: The ASX medtechs tackling respiratory illnesses
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Rise and Shine: Everything you need to know before the ASX opens
Closing Bell: Tech, Retail, and Banking stocks feel the heat as ASX tumbles over 1pc
ASX Small Caps Lunch Wrap: Whose bark could be worse than their flight this week?
Top 10 at 10: This is what happens when AstraZeneca selects your tech for a clinical trial
Adherium’s focus on US market could pay off big time for its novel asthma device
Closing Bell: Geopolitical tensions, China’s economy roil the ASX as Aussie dollar trades below US65c
Top 10 at 10: Piedmont gets green light to build ‘one of the lowest cost, most sustainable lithium hydroxide operations in the world’
Check Up: Earnings season is almost here. Here’s how ASX biotech investors should read the 4C Report
